PHILADELPHIA, June 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ('Carisma' or the 'Company'), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ('Development Candidate'), under its collaboration with Moderna, Inc.

费城，2024年6月27日/PRNewswire/--Carisma Therapeutics Inc.（纳斯达克：CARM）（“Carisma”或“公司”）是一家专注于发现和开发创新免疫疗法的临床阶段生物制药公司，今天宣布提名第一位开发候选人（“开发候选人”），与Moderna，Inc.合作。

The Development Candidate is an in vivo CAR-M targeting Glypican-3 ('GPC3') and is designed to treat solid tumors, including hepatocellular carcinoma ('HCC'), the most prevalent type of liver cancer and the fastest-rising cause of cancer-related death in the U.S. This nomination triggers a $2 million milestone payment to Carisma..

开发候选人是一种靶向磷脂酰肌醇蛋白聚糖-3（“GPC3”）的体内CAR-M，旨在治疗实体瘤，包括肝细胞癌（“HCC”），这是美国最常见的肝癌类型，也是癌症相关死亡上升最快的原因。这一提名触发了对Carisma的200万美元里程碑式付款。。

The nomination of this Development Candidate leverages Carisma's expertise in engineering chimeric antigen receptor monocytes and macrophages ('CAR-M') with Moderna's mRNA and lipid nanoparticle platform to create a novel in vivo cell therapy for oncology. Pre-clinical data demonstrated that the Development Candidate can successfully create CAR-M directly in vivo, redirecting endogenous myeloid cells to attack cancer cells..

该开发候选人的提名利用了Carisma在工程嵌合抗原受体单核细胞和巨噬细胞（“CAR-M”）与Moderna的mRNA和脂质纳米颗粒平台方面的专业知识，为肿瘤学创造了一种新型的体内细胞疗法。临床前数据表明，开发候选者可以直接在体内成功创建CAR-M，重定向内源性骨髓细胞以攻击癌细胞。。

'The nomination of the first Development Candidate underscores our productive collaboration with Moderna to develop mRNA-based in vivo CAR-M cell therapies,' said Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer at Carisma. 'The Development Candidate targets GPC3, a tumor antigen that is highly expressed in HCC.

Carisma联合创始人兼首席科学官、医学博士Michael Klichinsky说：“第一位开发候选人的提名突显了我们与Moderna在开发基于mRNA的体内CAR-M细胞疗法方面的卓有成效的合作。”发展候选者靶向GPC3，一种在HCC中高度表达的肿瘤抗原。

This milestone represents a significant step forward in the development of immunotherapies for solid tumors, and an advance for the in vivo cell therapy field.'.

这一里程碑标志着实体瘤免疫疗法的开发向前迈出了重要一步，也是体内细胞疗法领域的进步。

Lin Guey, PhD, Chief Scientific Officer of Therapeutics Research Ventures and Biotherapeutics at Moderna, stated, 'We are thrilled with the significant progress we've made in advancing in vivo CAR-M therapies alongside Carisma. We eagerly anticipate further development of the nominated candidate for patients with solid tumors, and we look forward to continued success as we develop additional in vivo CAR-M together to bring new therapies to patients with HCC and other cancers.'.

Moderna治疗学研究风险投资和生物治疗学首席科学官LinGuey博士表示，“我们对与Carisma一起推进体内CAR-M疗法取得的重大进展感到兴奋。我们热切期待着实体瘤患者提名候选人的进一步发展，我们期待着继续取得成功，因为我们共同开发了额外的体内CAR-M，为HCC和其他癌症患者带来新的治疗方法。”。

The in vivo CAR-M program targeting GPC3 is being developed under the 2022 strategic collaboration agreement between Carisma and Moderna to discover, develop, and commercialize in vivo engineered CAR-M therapeutics for the treatment of cancer. In addition to this program, Moderna has nominated four undisclosed oncology research targets under the collaboration.

针对GPC3的体内CAR-M计划正在根据Carisma和Moderna之间的2022年战略合作协议进行开发，以发现，开发和商业化用于治疗癌症的体内工程CAR-M疗法。除了这个项目之外，Moderna还提名了四个未公开的肿瘤学研究目标。

Carisma is responsible for the discovery and optimization of development candidates, while Moderna will lead the development and commercialization of resulting therapeutics..

Carisma负责开发候选药物的发现和优化，而Moderna将领导由此产生的治疗药物的开发和商业化。。

About Carisma Therapeutics

关于Carisma Therapeutics

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response.

Carisma Therapeutics Inc.是一家临床阶段的生物制药公司，专注于利用我们专有的巨噬细胞和单核细胞工程平台开发用于治疗癌症和其他严重疾病的转化性免疫疗法。我们已经创建了一个全面的，分化的专有细胞治疗平台，专注于工程化巨噬细胞和单核细胞，这些细胞在先天性和适应性免疫反应中起着至关重要的作用。